Lisa Henderson

A common takeaway in our exploration of "Emerging Biopharma" appears to be that these companies are those that go beyond pure discovery-and put equal efforts into the pivot to potential commercialization.

Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.

While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?

My first gathering of Pharm Exec's Editorial Advisory Board was both an honor and a learning experience-about us, the industry, and maintaining our mission to the our readers.

Amid new efforts to inspire more physicians to engage their patients about clinical research, turning that vision into tangible gains in trial participation remains tricky.

Amid rapid shifts in technology and consumer engagement, Pharm Exec explores how new models in hiring and recruitment-along with the evolution of the C-suite-are reshaping biopharma’s talent path of the future.

Pharma's evolving landscape in recent years has created the need to recruit experts from outside of industry-and establish new pathways for traditional executive roles in the life sciences.

The role of the medical affairs professional in the biopharma hierarchy has grown considerably in recent years, but challenges remain in its accent to true strategic partner with the C-suite.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.

Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders-call it the quest to see "what right looks like?"

The advent of immunocellular therapies marks a major milestone in pharma, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance,

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

Drawing from his research roots and the leadership lessons gained in melding business and culture in geographies across the globe, Ruud Dobber is busy steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.

Our annual look at the drug industry's pipeline-the progress and the setbacks-puts my thoughts on those people driving new science behind the scenes in pharmaceutical research.

Ruud Dobber, answers the question, "What is the most surprising thing you've learned about America or Americans since you moved here and took over the US last year?"

As we again highlight a roster of emerging leaders in pharma, I wanted to recognize Pharm Exec's own unique team behind the scenes.

A big thank you to you, our readers, for lending your voice to Pharm Exec's editorial mission-giving you the information you need and want. Click ahead for a look at some of the future topics we'll be tackling.

As more states approve the use of medical marijuana-and its rising profile as potential opioid alternative-industry and FDA are stepping up their focus on developing cannabis-derived therapies.

As we step further into the waters of value-based contracting arrangements, lessons learned must be shared-including the role of the patient in the equation.

There's no shortage of talent, expertise and passion in the biopharma industry. It's time for that talent to shine.

Recent PR disasters in other industries raise an important reputational question that can apply to pharma as well: do you want to be someone that works the system or improves the system?

Two topics in Pharm Exec this month-rare disease research and women in healthcare leadership-share a "common" thread.

No longer just hype, investing in big data is the path to the future for pharma, even if big returns aren't a direct result.

Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.

Recent events you may have missed on the global pharma scene.

Lisa Henderson discusses how role of social media in post-market adverse event reporting is finally being taken seriously by the FDA.

In December 2011, the President’s Bioethics Commission released its “Moral Science: Protecting Participants in Human Subjects Research“